ScripAmid a sweeping tightening of securities regulatory policies since late 2023, there has been a dearth of initial public offerings for bioventures in the Chinese mainland. But Hong Kong has just welcom
ScripTwo innovative drug-focused Chinese bioventures are trying their luck with public share sales on China’s Nasdaq-like STAR Market under the Shanghai Stock Exchange, ending a more than six-month break i